Advertisement

Nodular Lymphocyte Predominant Hodgkin's Lymphoma

  • Michelle A. Fanale
  • Anas Younes

Whereas it is estimated that 7800 new cases of Hodgkin’s lymphoma (HL) will be diagnosed in 2006, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) will only account for 3–8% of newly diagnosed HL (1, 2). The majority of the incidence is accounted for by the classical Hodgkin lymphoma (cHL) subtypes (nodular sclerosing, lymphocyte rich, lymphocyte depleted, and mixed cellularity). There exists today a large breadth of literature that describes the pathology and epidemiology and provides data that supports the current acceptable standard approaches for both front-line and relapsed/refractory treatment of CHL (3). Given the rarity of the diagnosis of NLPHL, there are significantly fewer publications that are available to establish treatment algorithms and predict both short-term and long-term outcomes. However, as more has become understood about the pathology that underlies the diagnosis of NLPHL, more studies have now come forth that provide the rationale and evidence to support stagebased treatment approaches for the care of patients with this unusual diagnosis.

Keywords

Hodgkin Lymphoma Overall Response Rate Classical Hodgkin Lymphoma Nodular Lymphocyte Predominant Hodgkin Lymphoma German Hodgkin Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Michelle A. Fanale
    • 1
  • Anas Younes
    • 1
  1. 1.University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations